MEDICAL NEWS SITES

f5d30afbe91132c8c58a0a92e16172b936725597-200x200.jpg?auto=format

OncLive

Poziotinib Shows Meaningful Activity in EGFR Exon 20–Mutant NSCLC


Poziotinib, when given at a daily dose of 16 mg, was found to demonstrate clinically meaningful activity when used in treatment-naïve patients with metastatic non–small cell lung cancer (NSCLC) who harbor EGFR exon 20 mutations, according to data from cohort 3 of the phase 2 ZENITH20 trial (NCT03318939) presented during the 2021 ESMO TAT Virtual Congress.1 Of 79 patients, 12 remained on treatment with the agent, with a median follow-up of 9.2 months. Twenty-two patients achieved a response with poziotinib, equating to an overall response rate (ORR) of 27.8% (95% CI, 18.4%-39.1%).


Read more

49eaaff47b7e8d8070c26130c1632c1dacfd6404-1420x1416.png?auto=format

OncLive

Heymach Homes in On Emerging Agents in EGFR Exon 20–Mutant NSCLC


Welcome to OncLive On AirTM! I’m your host today, Jessica Hergert. OncLive On AirTM is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. In today’s episode, sponsored by Takeda, we had the pleasure of speaking with John V. Heymach, MD, PhD, chair, professor, and David Bruton, Jr Chair in Cancer Research in the Department of Thoracic/Head and Neck Medical Oncology, and professor in the Department of Cancer Biology, Division of Cancer Medicine at The University of MD Anderson Cancer Center, to...


Read more

fe6d83b6d5fa51ca6a32796e6eb6f3dcfbdb6f5e-200x200.jpg?auto=format

OncLive

Frontline ICI Therapy Gains Traction Across NSCLC Settings


Treatment strategies for patients with advanced-stage non–small cell lung cancer (NSCLC) have shifted away from platinum-based doublet chemotherapy and toward combination strategies that include immune checkpoint inhibitors (ICIs). Data from the KEYNOTE-024 trial (NCT02142738) showed an overall survival (OS) benefit with pembrolizumab (Keytruda) in patients with advanced-stage NSCLC and PD-L1 expression on at least 50% of tumor cells.1 The data led to the first approval of an ICI for patients with PD-L1–positive advanced NSCLC, and since then a variety of ICIs have been show-ing increasing benefit across larger subsets of patients in the first-line setting, including those without PD-L1 expression, especially when used as part of a combinat...


Read more

783fcd1d8d50053f9937e41825af5611b2e1356b-1920x1080.jpg?auto=format

OncLive

CodeBreak 100: Phase 2 Trial of Sotorasib in KRASG12C Mutated Non–Small Cell Lung Cancer


Heymach Homes in On Emerging Agents in EGFR Exon 20–Mutant NSCLC


Read more

6401e7017fd5aa7ed59e91b4399a99ea52339ca3-480x270.jpg?auto=format

Targeted Oncology

FDA Approves Expanded Indication for Lorlatinib for Frontline ALK+ NSCLC


The FDA has expanded the approval for lorlatinib (Lorbrena) to include an indication for the first-line treatment of patients with ALK-positive non–small cell lung cancer (NSCLC).1 Lorlatinib is now indicated for the treatment of adult patients with metastatic NSCLC whose tumors harbor ALK alterations, as detected by an FDA-approved test. In addition, the FDA’s accelerated approval for the agent from November 2018 has been converted to a full approval.2 The application was reviewed through the FDA’s Real-Time Oncology Review Program as well as through the Project Orbis Program. The FDA simultaneously approved the Ventana ALK (D5F3) CDx Assay as a companion diagnostic for lorlatinib. The new indication for the ALK inhibitor was supported ...


Read more

ht_190611_keytruda_800x450.jpg

MedScape

Pembrolizumab SCLC Indication Withdrawn in US


Merck & Co is withdrawing the US indication for pembrolizumab (Keytruda) for metastatic small cell lung cancer (SCLC) in patients with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy, according to a company statement. The move does not affect any of the drug's other indications: the immunotherapy is used in the treatment of many different types of cancer. The SCLC indication had been granted an accelerated approval by the Food and Drug Administration (FDA) in 2019 based on tumor response rate and durability of response data from patient cohorts in two trials.


Read more

legionnella-test.jpg

Medical News Today

Legionnaires' disease: Symptoms, transmission, and causes


Legionnaires’ disease is a form of pneumonia that can happen when a person breathes in the Legionella bacteria. Most cases are due to poor water management. In 2015, around 6,000 people received a diagnosis of Legionnaire’s disease, also known as Pontiac disease, in the United States (U.S.). However, there may be more cases that are not detected. In 1 in 10 cases, it is fatal. The incidence of the disease increased nearly fourfold from 2000 to 2014. Here are some key points about Legionnaire’s disease.


Read more

91481.jpg

MedPageToday

Ending Cervical Cancer; Cancer and Suicide; COVID and Kids' Cancers


Patients with cancer have a high rate of suicide, and a new study provides insights into who those patients are. (Psycho-Oncology) President Biden met with members of Congress to discuss strategies to advance cancer research, the first step in an effort to rejuvenate a cancer initiative begun during the Obama administration. (Bloomberg) The FDA expanded approval of the ALK inhibitor lorlatinib (Lorbrena) to include first-line treatment of ALK-positive non-small cell lung cancer, Pfizer announced. An international survey of pediatric cancer specialists documents multiple adverse effects of the COVID-19 pandemic on care for children and adolescents with cancer.


Read more

cs-herpes-zoster-vaccine-600x400.jpg

MedPageToday

Hematological Malignancies and Pneumococcal Disease Risk


The risk of an invasive pneumococcal disease is up to 39 times higher in patients with hematological malignancies when compared to patients with other forms of cancer or individuals without cancer, according to a large cohort study with more than 80,000 person-years of observation.1 The increased risk of pneumococcal infection was persistent. And, though vaccination was recommended and reimbursed in the study population, most patients in the study were not vaccinated.1 Take Note A population-based study from Denmark showed a higher incidence of pneumococcal disease in adults with hematological malignancies compared with non-hematological malignancies or those without cancer. Less than 2% of those with hematologic malignancies had been vac...


Read more

6401e7017fd5aa7ed59e91b4399a99ea52339ca3-480x270.jpg?auto=format

Targeted Oncology

Toripalimab Rolling Submission of BLA Initiated for Nasopharyngeal Carcinoma


A rolling submission of the Biologics License Application (BLA) was initiated for toripalimab for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (NPC). The developer, Shanghai Junshi Biosciences Co., Ltd announced plans to submit the BLA back in September 2020, after the agent showed promise in the phase 1b/2 POLARIS-02 trial (NCT02915432) and was granted Breakthrough Therapy Designaton.1 “There has been limited development of treatment approaches for patients with advanced NPC in the United States [US]," Patricia Keegan, MD, chief medical officer of Junshi Biosciences, said in a statement.


Read more

woman-with-shoulder-pain-skeleton-showing.jpg

Medical News Today

Shoulder blade pain: Causes and treatment


Shoulder blade pain is a very common experience, with causes ranging from simple strains to serious conditions, such as heart attacks or liver problems. Determining the cause of shoulder blade pain can be difficult. People experiencing shoulder blade pain need to know the possible reasons for the pain and what precautions to take. In this article, we examine a variety of different causes of pain around the shoulder blades, along with what can be done to treat each problem. There can be various reasons for pain in the shoulder blades.


Read more

Pulmatrix_Logo.jpg

BioSpace

Pulmatrix Provides a Pipeline and Business Update


LEXINGTON, Mass., March 4, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today provides an update on its business and product pipeline. Pipeline and Business Updates: PUR1800: 3 of 15 patients have been dosed in the Phase 1b clinical study with endpoints including safety, tolerability and exploratory biomarkers to demonstrate target engagement and anti-inflammatory effect.


Read more

BioSpace

Checkpoint Therapeutics to Participate in H.C. Wainwright Global Life Sciences Virtual Conference


NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in the H.C. Wainwright Global Life Sciences Virtual Conference, taking place March 9-10, 2021. The company’s presentation will be available for on-demand viewing beginning on Tuesday, March 9, 2021, at 7:00 a.m. ET, on the Events page, located within the Investors section of Checkpoint’s website, for approximately 30 days. About Checkpoint Therapeutics Checkpoint Therapeutics, Inc.


Read more

;w=600;h=315

BioSpace

Associate Director, Competitive Intelligence, Oncology job with Gilead Sciences, Inc. | 2257712


United States - California - Foster CityGilead Sciences, Inc. is a research-based bio-pharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. With each new discovery and investigational drug candidate, we seek to improve the care of patients living with life-threatening diseases around the world. Gilead's therapeutic areas of focus include HIV/AIDS, liver diseases, cancer and inflammation, and serious respiratory and cardiovascular conditions.Inclusion is one of the company's five core values.


Read more

cell_carcinoma_GettyImages1219133242_Thumb.jpg

Medical News Today

Large cell carcinoma: Stages, treatment, prognosis, and more


There are two types of lung cancer: small cell lung cancer and non-small cell lung cancer. Large cell carcinoma is a type of non-small cell lung cancer. Non-small cell lung cancer (NSCLC) makes up around 80–85% of lung cancers. This article looks at what NSCLC is, its symptoms, causes, and treatment options. We also look at the prognosis and when a person should contact a healthcare professional. What is it? According to the American Cancer Society, the two main types of lung cancer are small cell lung cancer (SCLC) and NSCLC.


Read more

model-of-the-rib-cage.jpg

Medical News Today

6 possible causes of rib cage pain


Many cases of rib cage pain are not linked to serious conditions and resolve on their own or with minimal treatment. Others, however, are medical emergencies requiring immediate intervention. Rib cage pain is a common complaint that can be caused by factors, ranging from a fractured rib to lung cancer. The pain associated with the rib cage may be sudden and sharp or dull and aching. There are many possible causes of rib cage pain. A doctor will diagnose the underlying cause by a physical examination and imaging scans. Injury to the chest from falls, traffic collisions, and sports-related contact is the most common cause of rib cage pain.


Read more

305691_2200-1200x628.jpg

Medical News Today

Radon poisoning: Facts, exposure, and effects


Radon (Rn) is a naturally occurring element that develops from the radioactive decay of radium. Health authorities consider it a health hazard because of its radioactivity. The United States Environmental Protection Agency (EPA) classes radon as a carcinogen, meaning that radon poisoning can lead to cancer. It is the leading cause of lung cancer in non-smokers and the second leading cause in smokers. Radon is a health risk, as it is not detectable and does not cause noticeable symptoms until its transformation into lung cancer.


Read more

320352_2200-1200x628.jpg

Medical News Today

Budwig diet: What to eat, making the mixture, evidence, and risks


The Budwig diet, or Budwig protocol, is a diet plan that some people believe can support the treatment of cancer. Standard medical treatments for cancer include surgery, chemotherapy, and radiotherapy. Some people also look for complementary therapies that can support the treatment process. One such therapy is the Budwig diet. This diet involves the consumption of a flaxseed oil and cottage cheese mixture, as well as the avoidance of processed foods and animal fats. Flaxseed contains omega-3, a healthful fat that may reduce the levels of certain chemicals that contribute to cancer.


Read more

older-adult-coughing.jpg

Medical News Today

Coughs: Causes, symptoms, and treatments


A cough, also known as tussis, is a voluntary or involuntary act that clears the throat and breathing passage of foreign particles, microbes, irritants, fluids, and mucus; it is a rapid expulsion of air from the lungs. Coughing can be done deliberately or as part of a reflex. Although coughing can be a sign of a serious illness, more often, it will clear up on its own without the need for medical attention. In this article, we will cover the possible causes, diagnosis, and treatments for coughs. Here are some key points about coughs.


Read more

2cd67f9d20904730ad702cbef6314d18c1356acf-5000x3750.jpg?auto=format

Cancer Network

Fluorescent Marker Pafolacianine Sodium Receives Priority Review for Detection of Ovarian Cancer During Surgery


The FDA has accepted and granted priority review to a new drug application (NDA) for pafolacianine sodium injection (OTL38) for use in identifying ovarian cancer during surgical procedures, announced the agent’s developer On Target Laboratories, Inc.1 Pafolacianine sodium is a fluorescent marker made of near-infrared dye and a ligand that allows it to bind to receptors overexpressed in ovarian cancer cells. When injected, the agent binds to folate receptors and will illuminate when used under near-infrared light.


Read more

NEWS SITES

WireAP_c7b483a0e0a14f7087b85ec98cb147c5_16x9_992.jpg

ABC News

Walter Gretzky, father of NHL star Wayne Gretzky, dies at 82


TORONTO -- Walter Gretzky, the father of hockey great Wayne Gretzky, has died. He was 82. Wayne Gretzky said in a social media post Thursday night that his father battled Parkinson’s disease and other health issues the past few years. “It’s with deep sadness that Janet and I share the news of the passing of my dad,” Wayne Gretzky said. “He bravely battled Parkinson’s and other health issues these last few years, but he never let it get him down. “For me, he was the reason I fell in love with the game of hockey.


Read more

abc_news_default_2000x2000_update_16x9_992.jpg

ABC News

– Breaking News, Latest News, Headlines & Videos


Walter Gretzky, the father of NHL great Wayne Gretzky, has died at age 82. Wayne Gretzky announced the news on Twitter on Thursday, saying his father "bravely battled Parkinson's and other health issues over these last few years, but he never let it get him down." "For me, he was the reason I fell in love with the game of hockey," Wayne Gretzky wrote. "He inspired me to be the best I could be not just in the game of hockey but in life. We will miss him so much, but know that he's back with our mom and that brings me and my family peace.


Read more

defaultPromoCrop.png

New York Times

Site Map - January 5, 1961


Articles Hawks Hand Fourth Loss in Row to Rangers at Garden; RALLY BY CHICAGO BEATS BLUES, 3-2 Mikita's 2d Goal Subdues Rangers as All Scoring Is Done in Last Period Sailor Rescued in China Sea 12 Killed in Ruhr Explosion EMILE PELET Blaw-Knox Company Picks High Executive SOCIALISTS BEGIN TALKS; West European Party Heads Gather in Salzburg DETECTIVE CHIEF IN CITY RETIRING; Leggett, 61, to Quit April 30 -- Kennedy Cites 37 Years of 'Devoted Service' GLOVE TRIPS UP THIEF; Police Match It With Suspect in $23 Broadway Hold-Up Chemway Adds 3 to Board DOCKERS BOYCOTT CARGO FROM CUBA ALBANY NEWSMEN ELECT; Joseph W.


Read more

defaultPromoCrop.png

New York Times

Site Map - April 23, 1958


Articles Junior Title Boxing Canceled Article 10 -- No Title COL. EARL R. TASI-I DIES; Held First to Down Japanese Plane in Phihppines I JOBLESS TERMED FEDERAL PROBLEM Plasterers' Chief Resigns M'ELROY IS HEARD AS BATTLE BEGINS ON PENTAGON PLAN; Secretary Tells House Unit Bill Could Strip Command From Any Service Chief ROGERS VICTOR IN RING; Defeats Sonny Boy Williams -- Chuvalo Knocks Out King Football Giants Sign Webster Cut in Lending Rate Spreads in Nation; Chase Joins Move Trenton Names City Planner Ex-Officer Fiance Of Mary Griscom U.


Read more

defaultPromoCrop.png

New York Times

Site Map - March 23, 1957


Articles Obituary 1 -- No Title It Is a Wise Wife Who Serves the Coffee Hot INGERSOLL-RAND LIFTS SALES, NET; Both at New Highs Last Year --Volume Up by 30.3% and Earnings 31.2% MIDLAND STEEL PRODUCTS 1956 Net Slumped to $2,842,057 From $4,402,279 in 1955 DANA CORPORATION 6 Months' Net at $2.71 a Share, Compared With $3.92 OTHER COMPANY REPORTS COMPANIES ISSUE EARNING FIGURES SAN FRANCISCO HIT BY HEAVY QUAKES, WORST SINCE 1906; Supermarket Is Shaken Up by California Quakes Birth Notice 1 -- No Title PHILLIS SIMONDS ENGAGED TO WED; Garland Student Is Fiancee of Paul Ives Bartholet, an Alumnus of Columbia Feld--Livingston FRANKNESS HELPS IN BERMUDA TALK; Macmillan's Plain-Speaking Reported to Impress the President Greatly President is Impresse...


Read more

defaultPromoCrop.png

New York Times

Site Map - April 2, 1962


Articles Marine Safety Parley Set GREYHOUND CORP. RAISES EARNINGS; Net $1.69 a Share in 1961, Against $1.64 for 1960 MINERALS AND CHEMICALS WAGNER ASSAILS '62 LEGISLATURE; Says It Failed to Give City Funds to Balance Budget Difficulties Noted City 'Short Changed' WAR-READY TROOPS GIVEN UNSAFE TANKS POLICE WORK HELD IMPROVED IN STATE Lufthansa Plans African Route R.C.A. SET TO SELL WHIRLPOOL STOCK; 1,000,000 Share Offering Slated for Public Market Brand Pact to Stand Katzenbach Is in Line for Post As Deputy Attorney General; Legislative Expert Likely to Succeed Byron R.


Read more

JOURNALS

favicon.ico

Dove Press

Wnt blockers inhibit the proliferation of lung cancer stem cells | DDDT


Xueyan Zhang,1* Yuqing Lou,1* Xiaoxuan Zheng,1 Huimin Wang,1 Jiayuan Sun,1 Qianggang Dong,2 Baohui Han1 1Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, People’s Republic of China; 2Section of Cancer Stem Cells, Shanghai Cancer Institute, Shanghai Jiaotong University, Shanghai, People’s Republic of China *These authors contributed equally to this work Background: Previous study has confirmed that the occurrence of Wnt pathway activation is associated with risk of non-small-cell lung cancer recurrence.


Read more

gr1.jpg

Lung Cancer

Vaping and lung cancer – A review of current data and recommendations


Objectives Lung cancer is the most common cause of cancer mortality worldwide and, while tobacco smoke remains the primary cause, there is increasing concern that vaping and E-cigarette use may also increase lung cancer risk. This review concentrates on the current data, scholarship and active foci of research regarding potential cancer risk and oncogenic mechanisms of vaping and lung cancer. Materials and methods We performed a literature review of current and historical publications on lung cancer oncogenesis, vaping device/e-liquid contents and daughter products, molecular oncogenic mechanisms and the fundamental, potentially oncogenic, effects of electronic cigarette smoke/e-liquid products. Results E-cigarette devices and vaping fluids...


Read more

41392_2021_495_Fig1_HTML.png

Nature

SRSF1 inhibits autophagy through regulating Bcl-x splicing and interacting with PIK3C3 in lung cancer


Activation of autophagy is an important approach to inhibit tumorigenesis. Several key regulators of autophagy, Beclin1 for example, have been shown to undergo alternative splicing to generate functionally distinct isoforms.30 However, splicing factors that regulate these alternative splicing events, thereby modulating autophagy and tumorigenesis, are still elusive. To systematically identify splicing factors that might participate in autophagy regulation in A549 lung cancer cells, we performed a screen with shRNAs, which have been verified by ENCODE project,31 to deplete several dozens of RNA binding proteins, respectively, and determined the regulation of autophagy as judged by the change of LC3-II level.


Read more

favicon.ico

Dove Press

Superoxide Dismutase as an Intervention for Radiation Therapy-Associat | DDDT


The May 1954 issue of the journal Science included a paper which would have a major impact on the understanding of the pathoetiology of ionizing radiation’s toxic impact. For it was there that Rebecca Gerschman and her University of Rochester colleagues described a series of experiments demonstrating that radiation toxicity is associated with the generation of oxygen free radicals.1 The results described the impact of radiation-induced hydrolysis on the generation of reactive oxygen species, a process occurring in cells with every fraction of radiation therapy. Cells are 70% water, and thus water is an abundant target for ionizing radiation.


Read more

favicon.ico

Dove Press

Prognostic Implications of the Complement Protein C1Q and Its Correlat


Osteosarcoma (OS) is one of the most frequent types of primary cancers in adolescent malignant bone tumours, and its characteristics include high aggressiveness and early systemic metastasis.1,2 At present, a large number of studies have suggested that the prognosis of OS patients with distant metastasis is poor, and its pathogenesis is still unknown.3 Advanced surgical techniques combined with multiple chemotherapies in clinical settings have significantly improved the 5-year survival rate for OS patients by 55–70%.


Read more

favicon.ico

Dove Press

Phase-Transformation Nanoparticle-Mediated Sonodynamic Therapy: An Eff | IJN


Breast cancer is a malignant tumor and the most common cancer in women.1 Triple-negative breast cancer (TNBC) has the worst prognosis among breast cancers because of its aggressiveness and degree of malignancy.2,3 Once recurrence and metastasis of TNBC develop after surgery, the median survival time is only approximately 9 months.4 At present, chemotherapy is still the main treatment for TNBC. Unfortunately, the prognosis for patients with TNBC is unsatisfactory due to the inevitable drug resistance.


Read more

favicon.ico

Dove Press

Early Study of Tumor Abnormal Protein in Gastric Adenocarcinoma


Followed by lung cancer and liver cancer in men and breast cancer and lung cancer in women, gastric cancer is still the third leading cause of cancer-related death.1 At present, the treatment of gastric cancer is mainly surgical operation supplemented by chemotherapy, radiotherapy, targeted therapy, immunotherapy and supportive treatment. Some early gastric cancer can be treated by endoscopic resection, and advanced gastric cancer can be treated by open or laparoscopic gastrectomy and lymph node dissection.


Read more

favicon.ico

Dove Press

The therapeutic potential of targeting HYOU1 - OTT


The endoplasmic reticulum (ER) is involved in protein synthesis, post-translational modifications, and correct folding of proteins, and plays a key role in many cellular processes.1,2 The endoplasmic reticulum is highly sensitive to changes in a range of intracellular environment or extracellular stimuli, especially in malignant cells, including hypoxia, increased protein synthesis, impaired ubiquitination and proteasomal degradation, insufficient energy, nutrition, excessive or restricted substances, and imbalanced calcium levels.3–5 These stimuli can lead to accumulation of misfolded proteins in the endoplasmic reticulum cavity, and when the accumulation of misfolded proteins in the endoplasmic reticulum exceeds a certain level, the endop...


Read more

favicon.ico

Dove Press

Clinical Significance of Monitoring Circulating Free DNA and Plasma He | CMAR


Esophageal cancer is the eighth most highly diagnosed type of cancer and the sixth leading cause of cancer-related death worldwide.1,2 Its incidence and mortality continue to rise. Nearly half of the new cases of esophageal cancer worldwide are found in China, and esophageal squamous cell carcinoma (ESCC) is the predominant histological type.3 Due to the late-stage at diagnosis for most patients, the prognosis of ESCC patients remains poor, with an overall 5‑year survival rate of 15‑25%.4,5 Massive efforts have been made to develop diverse methods to detect early cancer, monitor treatment response and predict prognosis.6–10 To date, nevertheless, works to identify molecular markers in association with the pathogenesis and response to therap...


Read more

gr1.jpg

The Lancet

Public reporting of outcomes in radiation oncology: the National Prostate Cancer Audit


The public reporting of patient outcomes is crucial for quality improvement and informing patient choice. However, outcome reporting in radiotherapy, despite being a major component of cancer control, is extremely sparse globally. Public reporting has many challenges, including difficulties in defining meaningful measures of treatment quality, limitations in data infrastructure, and fragmented health insurance schemes. The National Prostate Cancer Audit (NPCA), done in the England and Wales National Health Service (NHS), shows that it is feasible to develop outcome indicators for radiotherapy treatment, including patient-reported outcomes.


Read more

41388_2021_1683_Fig1_HTML.png

Nature

PSPH promotes melanoma growth and metastasis by metabolic deregulation-mediated transcriptional activation of NR4A1


Kakadia S, Yarlagadda N, Awad R, Kundranda M, Niu J, Naraev B, et al. Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. Onco Targets Ther. 2018;11:7095–107. Sullivan MR, Mattaini KR, Dennstedt EA, Nguyen AA, Sivanand S, Reilly MF, et al. Increased serine synthesis provides an advantage for tumors arising in tissues where serine levels are limiting. Cell Metab. 2019;29:1410–1421. e1414. Gao S, Ge A, Xu S, You Z, Ning S, Zhao Y, et al.


Read more

CONFERENCES

European Society for Medical Oncology

EMA Recommends Extension of Therapeutic Indications for Cabozantinib and Nivolumab


On 25 February 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal products cabozantinib (Cabometyx) and nivolumab (Opdivo). The marketing authorisation holder for Cabometyx is Ipsen Pharma. The marketing authorisation holder for Opdivo is Bristol-Myers Squibb Pharma EEIG. The CHMP adopted an extension to an existing indication for Cabometyx as follows (new text in bold): Renal Cell Carcinoma (RCC) Cabometyx is indicated as monotherapy for the treatment of advanced RCC: in treatment-naïve adults with intermediate or poor risk, in adults following prior vascular endothelial growth fa...


Read more

FINANCE SITES

5f0b452f99f89bf6777317cc4d2759b8

Yahoo Finance

GO2 Foundation Leads Study to Improve Participation of Black Communities in Lung Cancer Clinical Trials


PR Newswire SAN CARLOS, Calif. and WASHINGTON, March 4, 2021 SAN CARLOS, Calif. and WASHINGTON, March 4, 2021 /PRNewswire/ -- GO2 Foundation for Lung Cancer (GO2 Foundation) announced its leadership in the launch of an important multi-institutional study to determine how to improve the participation of Black communities in lung cancer clinical trials. GO2Foundation for Lung Cancer (PRNewsfoto/GO2 Foundation for Lung Cancer) While participation in clinical trials by all cancer patients in the U.S.


Read more

e9a4a14a2aae4f13493017287515399a

Yahoo Finance

Oncocyte Announces Agreement with MultiPlan Network, Expanding Patient Access to DetermaRx™


Agreement adds access for 60 million covered lives at a negotiated price in line with CMS pricing for the test IRVINE, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, has signed an agreement with MultiPlan to participate in its networks. Through this agreement DetermaRx™ will now be available to those consumers with access to the PHCS and MultiPlan Network, MultiPlan’s national primary and complementary networks, at a pre-negotiated price per test.


Read more

PHARMA SITES

og-social.png

Merck Group

Healthcare - Merck Geschäftsbericht 2020


Im Bereich Healthcare erforschen, entwickeln, produzieren und vermarkten wir innovative verschreibungspflichtige Arzneimittel und Biopharmazeutika zur Behandlung von Krebserkrankungen, Multipler Sklerose (MS), Unfruchtbarkeit, Wachstumsstörungen sowie bestimmten Herz-Kreislauf- und Stoffwechselerkrankungen. Healthcare ist in vier Geschäftseinheiten aufgeteilt: Neurologie & Immunologie, Onkologie, Fertilität sowie General Medicine & Endokrinologie. Mit unserer Forschungs- und Entwicklungspipeline verfolgen wir eine klare Fokussierung: Wir wollen ein führender Anbieter innovativer Spezialprodukte in den Bereichen Onkologie, Immunonkologie, Neurologie und Immunologie werden. Im Geschäftsjahr 2020 generierte Healthcare 38 % des Konzernumsatzes...


Read more

og-social.png

Merck Group

(7) Collaboration and licensing agreements - Merck Annual Report 2020


The Group concludes material out-licensing agreements for intellectual property in the Healthcare business sector in particular. In the vast majority of cases, the granting of a license constitutes a distinct performance obligation that must usually be recognized at a point in time. Due to the uncertainty of development results and regulatory events, the recognition of contingent consideration usually does not take place until the result in question has materialized. In principle, sales-based and usage-based royalties are recognized only after the contract partner makes the corresponding sales or uses the intellectual property.


Read more

og-social.png

Merck Group

Letter from Stefan Oschmann - Merck Annual Report 2020


Without a doubt, 2020 was a very challenging year. The Covid-19 pandemic has upended the world. For us, it has also been extremely demanding – but it has not shaken us. In fact, we have successfully weathered the pandemic so far. That’s because the strengths of our business model with three innovation-driven business sectors have become particularly evident during the Covid-19 crisis. Thanks to our clear focus on science and technology, we are very well positioned even during economically challenging times. From the start, one thing was clear to us: The health and safety of our employees as well as business continuity would have top priority.


Read more

og-social.png

Merck Group

Business-related risks and opportunities - Merck Annual Report 2020


As a global company, we face political and regulatory changes in a large number of countries and markets. In the Healthcare business sector, the known trend toward increasingly restrictive requirements in terms of drug pricing, reimbursement, and the expansion of high-rebate groups is continuing. These requirements can negatively influence the profitability of our products, as can market referencing between countries, and the success of market launches. Foreseeable effects are taken into account as far as possible in the business sector’s plans.


Read more

og-social.png

Merck Group

Healthcare - Merck Annual Report 2020


Healthcare discovers, develops, manufactures, and markets innovative pharmaceutical and biological prescription drugs to treat cancer, multiple sclerosis (MS), infertility, growth disorders, and certain cardiovascular and metabolic diseases. Healthcare operates in four franchises: Neurology and Immunology, Oncology, Fertility, and General Medicine & Endocrinology. Our R&D pipeline positions us with a clear focus on becoming a global specialty innovator in oncology, immuno-oncology, neurology, and immunology. In 2020, Healthcare generated 38% of Group sales and 40% of EBITDA pre (excluding Corporate and Other).


Read more

SOCIAL MEDIA

ProfilePicture.png

Twitter

American Thoracic #maskUp NSCLC: 04/03/2021 11:01:01


Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for Stage II-IIIA (N1-N2) EGFR-mutant #NSCLC: Final overall survival analysis of CTONG1104 Phase III trial:


Read more

ProfilePicture.png

Twitter

Luca Cantini nsclc, immunotherapy: 04/03/2021 13:36:08


👉GRIM score variation as an easy to access tool for predicting clinical outcomes of NSCLC pts on first line pembro @OncoAlert #nsclc #immunotherapy


Read more

ProfilePicture.png

Twitter

Cancer Discovery ResearchWatch, LungCancer, Immunotherapy, ClinicalTrial, NSCLC: 04/03/2021 20:00:08


#ResearchWatch: Combination immune checkpoint blockade promising in operable non–small cell #LungCancer. @MDAndersonNews #Immunotherapy #ClinicalTrial #NSCLC https://t.co/azZeDig2jq


Read more

ProfilePicture.png

Twitter

Thomas Oliver : 04/03/2021 15:26:46


CT-DNA as a way to predict progression in EGFR mutated NSCLC? It was also able to identify the mechanism of resistance. Caveat being it can’t tell you if it has transformed into squamous etc. @MayoCancerCare grand rounds with Dr. Ramalingam @WinshipAtEmory


Read more

ProfilePicture.png

Twitter

OncLive.com lcsm: 04/03/2021 22:55:39


John V. Heymach, MD, PhD, of @MDAndersonNews discusses the incidence of EGFR exon 20 insertions in lung cancer and diagnostic challenges of identifying EGFR exon 20 insertions. #lcsm https://t.co/vDLLocUYse


Read more

ProfilePicture.png

Twitter

OncLive SOSS lcsm: 05/03/2021 01:00:51


LISTEN: John V. Heymach, MD, PhD, of @MDAndersonNews, discusses the incidence of EGFR exon 20 insertions in lung cancer, and diagnostic challenges of identifying EGFR exon 20 insertions #lcsm https://t.co/5TkhcvqOd2


Read more

ProfilePicture.png

Twitter

Gina (Columbus) Mauro : 05/03/2021 01:13:38


John V. Heymach, MD, PhD, of MD Anderson Cancer Center, discusses the diagnostic challenges of identifying EGFR exon 20 insertions in lung cancer.


Read more